Allogene Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.About ALLO
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
CEODavid D. Chang
CEODavid D. Chang
Employees229
Employees229
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2017
Founded2017
Employees229
Employees229
ALLO Key Statistics
Market cap324.74M
Market cap324.74M
Price-Earnings ratio-1.47
Price-Earnings ratio-1.47
Dividend yield—
Dividend yield—
Average volume2.39M
Average volume2.39M
High today$1.51
High today$1.51
Low today$1.41
Low today$1.41
Open price$1.48
Open price$1.48
Volume1.54M
Volume1.54M
52 Week high$3.78
52 Week high$3.78
52 Week low$0.8621
52 Week low$0.8621
Stock Snapshot
The current Allogene Therapeutics(ALLO) stock price is $1.45, with a market capitalization of 324.74M. The stock trades at a price-to-earnings (P/E) ratio of -1.47.
On 2025-12-04, Allogene Therapeutics(ALLO) stock moved within a range of $1.41 to $1.51. With shares now at $1.45, the stock is trading +2.8% above its intraday low and -4.0% below the session's peak.
Trading activity shows a volume of 1.54M, compared to an average daily volume of 2.39M.
Over the past 52 weeks, Allogene Therapeutics(ALLO) stock has traded between a high of $3.78 and a low of $0.86.
Over the past 52 weeks, Allogene Therapeutics(ALLO) stock has traded between a high of $3.78 and a low of $0.86.
Analyst ratings
79%
of 14 ratingsBuy
78.6%
Hold
14.3%
Sell
7.1%
People also own
Based on the portfolios of people who own ALLO. This list is generated using Robinhood data, and it’s not a recommendation.